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ABSTRACT 
Background: During the last decade it has been clarified that the inhalation of indium 
compounds can evoke alveolar proteinosis, cholesterol granuloma, pulmonary fibrosis and 
emphysema.  In this study, we aimed to elucidate the characteristics and time course of 
pulmonary disorders among indium workers using comprehensive pulmonary examinations at 
an indium-processing factory. 
Methods: Data for 84 male workers who underwent the examinations for nine consecutive 
years from 2002 to 2010 were analyzed regarding their symptoms, serum indium 
concentration (sIn), serum markers of interstitial pneumonia, pulmonary function test 
parameters and high-resolution computed tomography (HRCT) findings of the lungs. 
Results: In association with improvements in the work environment and work practice, the 
sIn levels decreased with significant reductions in the KL-6 and surfactant protein-D (SP-D) 
levels.  Regarding the HRCT findings, the interstitial lesions regressed partially, whereas 
emphysematous lesions increased progressively in the workers with high sIn values. 
FEV1/FVC decreased with the years and the rate of decrease was significantly greater in those 
with high sIn.  The biological half-life of sIn was estimated to be 8.09 years. 
Conclusions: The present findings suggest that the sIn, SP-D, KL-6 levels and radiological 
interstitial changes can be reduced in indium workers by alleviating exposure to indium, 
whereas emphysematous lesions can progress among those with a history of heavy exposure. 
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Key Messages 
What is the key question? 
► Does the progress of interstitial and/or emphysematous lesion in indium workers change 
by alleviating exposure to indium? 
 
What is the bottom line? 
► Because permanent emphysematous changes may be evoked under heavy exposure to 
indium compounds, it is necessary to reduce exposure to indium-containing particles and 
detect lung disorders caused by indium as early as possible. 
 
Why read on? 
► This comprehensive study, for the first time, examined the same workers in an indium 
plant for nine consecutive years, showing different longitudinal patterns of interstitial and 
emphysematous lesions in patients with indium lung after stopping or decreasing the 
exposure to the inhaled indium compounds. 
 
Key words: indium-tin oxide, occupational lung disease, interstitial pneumonia, pulmonary 
emphysema, pulmonary alveolar proteinosis 
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INTRODUCTION 
Indium is a rare metal that is primarily used in the form of indium-tin oxide (ITO), a 
sintered material consisting of 90% indium oxide (In2O3) and 10% tin oxide (SnO2), to 
produce flat panel displays, such as liquid-crystal displays.  Recently, indium use has sharply 
increased; the world demand for indium in 2007 was approximately four times higher than in 
1999.[1] 
  
  In 2001, a 29-year-old male who was a ITO surface grinder died of interstitial pneumonia 
with bilateral pneumothorax,[2] constituting the first reported case of indium-related lung 
disease.  In 2002, we conducted a comprehensive study at the ITO plant where the above 
patient was employed and reported that interstitial lung disorders characterized by 
abnormalities on high-resolution computed tomography (HRCT) and the elevation of serum 
KL-6 were observed in a significant number of indium-processing workers.[3]  Furthermore, 
workers with serum indium (sIn) concentrations in the highest quartile had a history of 
significantly longer periods of exposure, greater HRCT changes, lower diffusing capacity of 
the lung for carbon monoxide (DLco) and higher KL-6 levels compared with those with sIn 
concentrations in the lowest quartile.  According to these findings, we proposed that inhaled 
indium compound may be potential new cause of occupational lung disease (“indium 
lung”).[1 3]  This hypothesis was subsequently confirmed in different populations of indium 
workers.[4]  Combining the data obtained from 12 factories, including ours, and one 
research laboratory, Nakano et al.[5] reported a strong dose-response relationship between the 
serum indium level and effects on the lungs. 
 
  As of May 2013, nine cases of interstitial lung disease from Japan[6-11] and three cases of 
alveolar proteinosis from the US[12] and China[13] had been reported.  Exposure to indium 
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compounds has been suggested to cause a novel lung disease consisting of alveolar 
proteinosis, cholesterol granuloma, pulmonary fibrosis and emphysema, accompanied by 
pneumothorax in severe cases.[14]  The work environment and practice at ITO plants, where 
most cases have been reported, have considerably improved, and workplace changes have 
been implemented among heavily exposed workers over the last decade.  In this study, we 
conducted a longitudinal surveillance for nine consecutive years starting in 2002 of 84 male 
indium workers at an indium plant, where a cross-sectional study of 108 indium-processing 
workers was previously conducted,[3] to elucidate the clinical course of indium lung and the 
effects of reduced exposure. 
 
 
MATERIALS AND METHODS 
Study design and subjects 
  The present study was conducted as part of the health maintenance program for the 
employees and approved by the medical professional committee that oversees the health 
maintenance program of the plant.  
 
  A comprehensive respiratory examination program was conducted annually from 
2002-2010 for workers who were formerly and/or currently engaged in indium processing.  
The study design has been reported elsewhere and consisted of examinations of signs and 
symptoms, pulmonary function tests, HRCT of the lungs and measurements of the sIn 
concentration and serum markers of interstitial lung disease.[3]  Five hundred and fifteen 
individuals received an examination at least once, among whom 108 male workers underwent 
examinations in 2002 (reported as a cross-sectional study[3]).  After excluding the data for 
24 subjects who failed to undergo an examination for one or more years, we analyzed the data 
6 
 
of 84 male workers (Figure 1).  The exposure period for these workers was 9.7±4.8 years 
(Table 1).  During the study period, workers with significant interstitial change on chest 
X-rays or HRCT, emphysematous changes accompanied by elevated KL-6 and/or SP-D levels, 
or high sIn concentrations (2002-2006: no criteria, 2007-2008: >20 ng/ml, 2009-: >10 
ng/ml) were transferred to non-indium sections of the workplace.  Thirty-seven of the 84 
workers had stopped working at ITO before the last year of the present surveillance period 
(Table 1, “former workers in 2010”).  In a previous report,[3] we confirmed that all variables, 
including functional, radiological and biochemical parameters, were qualitatively similar 
between the formerly and currently employed indium-exposed workers with similar exposure 
periods; therefore, we combined the data for the former and current workers to analyze the 
time course of the disease.  All subjects provided their informed consent prior to initiation of 
the analysis in this study.  In both the Figures and Tables, the personal information was 
carefully anonymized. 
 
  Because the severity of lung disorder caused by indium inhalation is correlated with the sIn 
concentration,[3 5] we classified all workers into four groups according to their sIn 
concentrations measured in the first year: Group-1, <3.7; Group-2, 3.7-9.9; Group-3, 
10.0-22.4; Group-4, >22.5 ng/ml.  No differences were observed between the four groups in 
terms of age, prevalence of smokers or smoking indices.  We analyzed chronological 
changes in the variables among all participants and each of the four groups. 
 
Improvements in the work environment and practice 
The ITO processing work environment has steadily improved in addition to the 
introduction of various protective devices for workers.  As a result, the indium concentration 
in the air, as measured in accordance with the Working Environment Measurement Law 
7 
 
established by the Japan Industrial Safety and Health Association (JISHA), has gradually 
decreased (Figure 2), and it can be assumed that the new indium burden has decreased for the 
study population as a whole.  
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Table 1.  Worker characteristics 
 All Group-1  Group-2 Group-3 Group-4 
Serum indium concentration, ng/mL 0.2-126.7 0.2-3.6 3.7-9.9 10.0-22.4 22.5-126.7 
Subjects, n 84 21 21 21 21 
  Former workers, n (in 2010) 37 6 5 9 17 
 Former workers, n (in 2002) 21 6 4 3 8 
Age, yr (in 2002) 33.9 ± 7.9 35.9 ± 8.4 33.7 ±7.8 32.8 ± 9.1 33.3 ± 6.1 
Exposure period, years (in 2010) 9.7 ± 4.8 7.0 ± 4.5 9.0 ± 4.2 11.6 ± 4.3 11.5 ± 4.5 
Period from first exposure, years (in 2010) 14.5 ± 4.8 12.7 ± 5.4 13.1 ± 4.0 14.4 ± 4.1 17.7 ± 3.8 
Period from last exposure, years *(in 2010) 3.9 ± 5.3 4.1 ± 6.4 3.3 ± 6.2 2.2 ± 3.3 5.9 ± 3.9 
Smokers (current and/or former), n (in 2010) 
 (Smokers in subjects, % (in 2010))  
68  
(81.0%) 
18 
(85.7%) 
19 
 (90.5%) 
16 
 (76.2%) 
15 
 (71.4%) 
Smoking history, pack-years (in 2010) 14.4 ± 9.0 16.2 ± 9.0 15.7 ± 9.1 12.0 ± 8.7 13.4 ± 8.6 
Data for age, exposure period and smoking history are expressed as the means ± SD. Period from last exposure was calculated 
among the former workers. *Period from the last exposure was assumed to be 0 in the current workers. The value of mean 
pack-years is calculated only in the smokers. 
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Measurements 
  The measurements obtained were those previously described.[3]  Specifically, the subjects’ 
respiratory signs (rales, clubbed finger, cyanotic changes on finger nails) and symptoms 
(cough, sputum and exertional dyspnea) were examined according to the Japanese 
Pneumoconiosis Questionnaire.[15] 
 
Measurement of the serum KL-6, SP-D and indium concentrations 
  The serum KL-6 and surfactant protein-D (SP-D) levels were measured using an 
electrochemiluminescence immunoassay (Special Reference Laboratory, Tokyo, Japan), and 
the sIn concentration was measured by JISHA using inductively coupled plasma mass 
spectrometry (ICP-MS; Agilent Technologies, Santa Clara, CA, USA).  The serum SP-D 
levels had been measured since 2004.  The KL-6 levels obtained in 2010 were omitted due 
to a temporal mechanical failure to measure KL-6 during this year. The SP-D levels obtained 
in 2008-2009 were excluded from the analysis due to a change in the measuring kit for SP-D 
in 2008-2009.   
 
Pulmonary function tests 
  Spirometry parameters, including the vital capacity (VC), forced expiratory volume in one 
second (FEV1), DLCO and total lung capacity (TLC), were obtained using previously 
described methods.[3] 
 
HRCT of the lungs 
  Three levels (bilateral upper, middle and lower lung fields) of the lung on HRCT were 
selected to score interstitial and emphysematous changes.  The scoring method, a modified 
10 
 
form of the Japanese Respiratory Society guidelines for the diagnosis and treatment of 
COPD,[16] was utilized as previously described.[3]  Images of the three levels of the lungs 
were visually scored bilaterally for interstitial (ground-grass opacity or reticulonodular 
shadows) and emphysematous changes (low attenuation areas or bullae) on a scale of 0-5 by 
the same two pulmonologists independently.  The total score of six images was obtained, and 
the average total score for the two readers was adopted as the individual’s score for interstitial 
and emphysematous changes, respectively.  HRCT scoring was performed at the end of the 
study with the films displayed sequentially, while subject identifiers were blinded to the 
readers.  The HRCT scores for 2008 were unavailable because low-dose helical CT was 
conducted rather than HRCT to explore the existence of lung cancer in that year. 
The difference in scores between the two examiners was either 0 or one in 64% and 90% 
for interstitial and emphysematous changes, respectively (Spearman’s rank correlations 0.75 
and 0.77, respectively).  If the difference in score was equal to or greater than two, then the 
two examiners discussed and reevaluated the scores independently, and the average of the 
newly reevaluated scores was adopted. 
 
Statistical analysis 
  For continuous variables, the data distribution was examined and appropriate 
transformation was performed to obtain an approximately normal distribution prior to the 
analysis.  For assessing intra-individual changes of the parameters in each subject during the 
observation years, a single linear regression model was applied with the examination 
parameter as a dependent variable and study year as an independent variable, and the slope of 
the former against the latter was employed as an average annual change (AAC) of the 
examination parameter.  Dunnett’s test or Steel’s test was applied for testing the AAC 
between the lowest sIn group (reference group) and those of the other three groups.  To test 
11 
 
the year-by-year trend of the parameters, a single or multiple linear regression model was 
applied for continuous variables and the Cochran-Armitage trend test was used for the 
prevalence data. Holm’s method was used to avoid overestimation by multiple comparisons.  
The interaction between annual intra-individual time point variations and inter-group 
variations was tested using an ANOVA for repeated measurements with an adjusted degree of 
freedom for the F value using the Huynh-Feldt correction. All statistical analyses were 
performed using the JMP version 10.0.2/11.0.0 software program (SAS Institute). Statistical 
significance was considered to exist at p<0.05.  
 
 
RESULTS  
Respiratory symptoms 
No obvious trends were observed regarding changes in the respiratory symptoms.  None 
of the workers complained of dyspnea in 2002, whereas three workers in Group-4 complained 
of exertional dyspnea in 2010 (two of the three workers were non-smokers and the remaining 
one was an ex-smoker). Their sIn values in 2002 were 126.76, 98.76, and 40.42 ng/ml, 
respectively, and the former two had the highest sIn levels among the 84 subjects.  Moreover, 
their interstitial change scores on HRCT were among the largest (14.5, 17.0, 17.0, 
respectively) and they also exhibited emphysematous changes in 2002. Accordingly, the sIn 
level and interstitial HRCT changes may be surrogate makers of symptomatic deterioration.  
 
Serum indium level  
The mean sIn level tended to decrease gradually from 2002 overall, as well as in each 
group (Table 2).  The mean value of the sIn level for all subjects decreased from 18.9 in 
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2002 to 11.7 ng/ml in 2010.  The individual slope of sIn over time was negative in 77 
workers, regardless of whether they left or stayed in indium sections. 
 
Estimated biological half-life of serum indium 
The biological half-life of sIn was calculated from the rate of reduction in the sIn 
concentration obtained by plotting the sIn concentration against the number of years since 
quitting work in indium processing.  The data for the participants who had quit handling 
indium for more than three years were analyzed (n=34); 26 workers were current or former 
smokers and eight were never-smokers.  The median (interquartile range) half-life was 8.09 
years (5.91-13.79), which did not correlate with the subjects’ smoking history.  In order to 
elucidate the effects of the indium burden on the biological half-life of sIn, we divided the 
workers into three groups according to the sIn concentrations measured just before stopping 
indium processing: <3.0 (n=6), 3.1-10.0 (n=7) and >10.0 ng/ml (n=21).  The median half-life 
in the >10.0 ng/ml group was 8.95 years (7.49-12.21), which was longer than those observed 
in the groups with lower sIn concentrations (5.80 and 6.63, respectively). 
  
Serum KL-6 and SP-D 
The mean serum KL-6 levels tended to decrease in 2002 to 2009 overall, as well as in each 
group (Table 2).  The mean serum SP-D levels also tended to decrease significantly from 
2004 to 2010 overall (Table 2).  Additionally, the prevalence of workers with an abnormally 
elevated KL-6 or SP-D level decreased (Table 3). 
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Table 2.  Chronological changes in the sIn , KL-6, and SP-D levels 
  
2002 2003 2004 2005 2006 2007 2008 2009 2010 P for trend * 
sIn 
All 8.6 (4.2) 7.5 (4.7) 8.0 (4.3) 6.5 (5.1) 4.4 (7.2) 5.6 (5.4) 5.8 (4.8) 4.9 (5.2) 4.9 (4.9) 0.0019 
Gr-1 1.2 (2.4) 1.0 (3.8) 1.2 (3.3) 0.8 (3.9) 0.3 (4.7) 0.6 (3.9) 0.7 (2.9) 0.6 (4.1) 0.6 (3.4) 0.0071 
Gr-2 6.0 (1.3) 5.3 (1.3) 5.7 (1.4) 5.0 (1.4) 3.4 (2.1) 4.3 (1.5) 4.3 (1.5) 4.2 (1.5) 4.0 (1.6) < 0.0001 
Gr-3 16.2 (1.3) 14.1 (1.3) 14.3 (1.4) 12.7 (1.5) 11.1 (1.5) 11.8 (1.6) 11.1 (1.5) 8.8 (1.5) 8.8 (1.5) < 0.0001 
Gr-4 46.4 (1.6) 41.4 (1.7) 41.0 (1.7) 37.8 (1.7) 33.5 (1.7) 32.8 (1.8) 33.6 (1.7) 28.8 (1.7) 27.9 (1.7) < 0.0001 
KL-6 
All 448.0 (2.1) 404.2 (2.0) 376.2 (1.9) 348.0 (1.9) 352.2 (1.8) 297.7 (1.8) 289.9 (1.7) 275.0 (1.8) NA < 0.0001 
Gr-1 243.8 (1.5) 222.4 (1.4) 220.0 (1.4) 227.1 (1.5) 228.8 (1.4) 205.8 (1.4) 198.2 (1.4) 187.9 (1.4) NA 0.0102 
Gr-2 383.8 (1.7) 345.4 (1.7) 327.3 (1.7) 293.8 (1.6) 316.7 (1.6) 266.3 (1.5) 253.7 (1.4) 258.3 (1.6) NA 0.0002 
Gr-3 452.2 (2.0) 418.0 (1.7) 360.8 (1.7) 328.2 (1.7) 339.9 (1.7) 259.3 (1.4) 265.8 (1.5) 239.7 (1.6) NA < 0.0001 
Gr-4 952.2 (1.7) 831.7 (1.7) 770.8 (1.7) 669.3 (1.7) 624.4 (1.8) 552.6 (1.8) 528.5 (1.7) 491.7 (1.8) NA < 0.0001 
SP-D 
All 
  
75.0 (1.8) 65.7 (1.7) 61.9 (1.9) 53.5 (1.8) NA NA 39.8 (2.3) < 0.0001 
Gr-1 
  
57.1 (1.7) 51.9 (1.6) 49.4 (1.9) 46.7 (1.8) NA NA 34.4 (2.2) 0.0049 
Gr-2 
  
57.9 (1.6) 52.1 (1.5) 48.2 (1.7) 42.7 (1.8) NA NA 30.2 (2.2) 0.0001 
Gr-3 
  
73.5 (1.7) 64.9 (1.6) 57.8 (1.8) 47.8 (1.6) NA NA 33.7 (2.2) < 0.0001 
Gr-4 
  
130.2 (1.6) 106.3 (1.7) 106.4 (1.6) 85.7 (1.7) NA NA 71.3 (1.9) 0.0002 
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Data are expressed as the geometric means (geometric SD).  *: test for chronological trend by applying single regression model. sIn: serum indium 
concentrations, SP-D: surfactant protein-D, Gr: group, NA: not available, Gr-1: sIn < 3.7 ng/ml, Gr-2: 3.7 ng/ml < sIn < 9.9 ng/ml, Gr-3: sIn 10.0 ng/ml < 
sIn < 22.4 ng/ml, Gr-4: 22.5 ng/ml < sIn. 
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Table 3.  The prevalence (%) of workers with abnormally elevated KL-6 and SP-D levels 
 2002 2003 2004 2005 2006 2007 2008 2009 2010 P for trend * 
KL-6           
All 39.3 35.7 32.1 27.4 25.0 15.5 14.3 13.1 - < 0.0001 
Gr-1 4.8 0 0 9.5  4.8 0 0 0 - 0.0173 
Gr-2 19.0 19.0 14.3 9.5  9.5  9.5  4.8  4.8 - 0.0007 
Gr-3 47.6 38.1 28.6 19.0 19.0  4.8  9.5  9.5 - < 0.0001 
Gr-4 85.7 85.7 85.7 71.4 66.7 47.6 42.9 38.1 - 0.0003 
SP-D           
All   26.2 17.9 19  11.9 - - 7.1 < 0.0001 
Gr-1    9.5 0 0  4.8 - - 0 0.0137 
Gr-2    9.5 0  4.8 0 - - 0 0.0007 
Gr-3   14.3  9.5  9.5  4.8 - -  4.8 0.0001 
Gr-4   71.4 61.9 61.9 38.1 - - 23.8 0.0001 
All data are expressed as %.  The data for KL-6 in 2010 and SP-D in 2008 and 2009 were not available due to technical reasons. SP-D: 
surfactant protein-D. *: The Cochran-Armitage trend test was used to test the significance of annual trends among the parameters. Gr-1: 
serum indium level (sIn) < 3.7 ng/ml, Gr-2: 3.7 ng/ml < sIn < 9.9 ng/ml, Gr-3: sIn 10.0 ng/ml < sIn < 22.4 ng/ml, Gr-4: 22.5 ng/ml < sIn. 
The cut-off values of abnormal KL-6 and SP-D levels were > 500 U/ml and > 110 ng/ml, respectively. 
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Radiological findings 
  During the nine-year study period, the interstitial HRCT score decreased overall but tended 
to remain stable during the latter half of the surveillance (Figure 3a and online supplement).  
Conversely, the emphysematous lesions on HRCT showed continuous progression in the 
highest sIn group (Figure 3b and online supplement).  No differences in the average annual 
changes in the emphysematous scores were observed among current, past and never-smokers 
even in the highest sIn group (data not shown).  No lung cancer was identified according to 
low-dose helical CT. 
 
Pulmonary function tests 
No consistent changes were observed in %FEV1 and %TLC in any group (Table 4).  
Conversely, %VC in all groups and %DLCO in Group-3 slightly increased. The FEV1/FVC in 
Groups-2 to 4 decreased over time.  The average annual decline in the FEV1/FVC was 
significantly greater in Group-4 compared with Group-1 (see online supplement).  
The %VC, %FEV1, %DLco and %TLC in Group-4 were lower than those in the other groups 
during most years.  There were no differences between the smokers and non-smokers 
regarding the relationship between the smoking history and annual changes 
in %VC, %FEV1, %DLCO and %TLC (data not shown).
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Table 4.  Chronological changes of the pulmonary function tests 
  Pulmonary function test by year 
    2002 2003 2004 2005 2006 2007 2008 2009 2010 P for trend * 
%VC 
(%) 
All 98.3 ± 11.4 100.2 ± 11.7 98.4 ± 12.1 101.0 ± 11.9 100.9 ± 11.5 102.6 ± 11.5 105.0 ± 11.5 106.9 ± 12.3 102.5 ± 11.6 < 0.001 
Gr-1 102.1 ± 9.7 104.2 ± 9.1 102.7 ± 10.1 105.1 ± 10.5 104.6 ± 10.0 105.8 ± 9.7 107.2 ± 9.5 109.1 ± 11.2 104.8 ± 8.7 0.0327 
Gr-2 99.7 ± 12.1 101.6 ± 11.8 99.9 ± 11.6 103.2 ± 11.9 102.9 ± 11.5 104.6 ± 11.1 107.0 ± 13.0 108.9 ± 13.0 103.6 ± 12.7 0.0103 
Gr-3 98.6 ± 11.7 101.1 ± 12.3 99.8 ± 13.0 101.3 ± 12.6 101.2 ± 11.4 103.7 ± 12.6 106.4 ± 11.6 107.1 ± 12.4 104.6 ± 11.8 0.0053 
Gr-4 92.6 ± 10.7 93.7 ± 11.1 91.2 ± 11.0 94.6 ± 10.5 95.1 ± 11.3 96.5 ± 10.9 99.5 ± 10.6 102.5 ± 12.1 96.9 ± 11.5 0.0010 
%FEV1 
(%) 
All 92.7 ± 10.4 93.3 ± 12.0 92.1 ± 12.7 92.0 ± 12.4 91.3 ± 12.5 92.9 ± 11.4 94.9 ± 12.0 94.6 ± 16.3 92.8 ± 12.9 0.3132 
Gr-1 96.1 ± 5.9 96.2 ± 6.7 96.5 ± 8.2 95.5 ± 9.3 95.3 ± 5.9 96.9 ± 8.0 97.7 ± 9.5 95.7 ± 23.4 96.9 ± 11.0 0.7717 
Gr-2 94.0 ± 9.9 95.7 ± 11.2 93.4 ± 10.4 93.9 ± 10.8 91.9 ± 9.8 93.7 ± 10.1 96.4 ± 11.5 96.3 ± 12.0 92.4 ± 11.2 0.9350 
Gr-3 95.1 ± 10.6 96.0 ± 11.9 95.3 ± 12.2 94.9 ± 11.5 94.2 ± 12.3 96.5 ± 10.7 98.5 ± 10.7 98.8 ± 12.2 96.3 ± 12.3 0.2819 
Gr-4 85.6 ± 11.5 85.5 ± 14.1 83.1 ± 14.9 83.9 ± 14.4 83.6 ± 15.1 84.5 ± 12.5 87.1 ± 13.2 87.6 ± 13.5 85.6 ± 14.4 0.5114 
FEV1% 
(%) 
All 82.8 ± 7.0 81.5 ± 7.1 81.2 ± 7.6 80.1 ± 8.6 79.9 ± 9.0 79.8 ± 7.9 78.8 ± 8.1 78.8 ± 8.3 78.6 ± 8.2 < 0.001 
Gr-1 82.4 ± 5.8 80.9 ± 5.8 81.1 ± 6.2 79.6 ± 6.7 79.2 ± 6.1 79.6 ± 6.1 78.7 ± 6.3 79.4 ± 6.6 79.8 ± 6.7 0.0646 
Gr-2 82.4 ± 6.1 81.6 ± 6.1 81.3 ± 6.7 79.8 ± 7.3 79.8 ± 6.2 80.4 ± 8.6 78.7 ± 7.1 78.7 ± 6.9 77.5 ± 6.6 0.0041 
Gr-3 84.9 ± 7.1 83.8 ± 6.4 83.3 ± 6.7 82.5 ± 7.9 82.4 ± 7.8 81.9 ± 7.8 81.6 ± 7.9 81.9 ± 7.5 80.6 ± 7.9 0.0279 
Gr-4 81.3 ± 8.9 79.7 ± 9.3 79.2 ± 10.0 78.4 ± 11.7 78.3 ± 13.4 77.1 ± 9.3 76.1 ± 10.3 75.3 ± 10.7 76.5 ± 10.6 0.0239 
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%DLCO 
(%) 
All 115.4 ± 16.5 110.1 ± 18.2 105.2 ± 17.7 104.1 ± 17.0 109.1 ± 18.0 113.0 ± 19.1 119.3 ± 19.8 112.3 ± 18.6 114.0 ± 19.9 0.0159 
Gr-1 124.4 ± 14.0 117.6 ± 15.0 115.6 ± 12.7 113.0 ± 12.8 119.6 ± 18.3 121.6 ± 15.6 128.0 ± 17.5 121.0 ± 14.2 125.9 ± 13.9 0.6671 
Gr-2 115.2 ± 11.5 110.1 ± 14.1 105.6 ± 11.6 105.0 ± 11.7 108.7 ± 14.6 112.6 ± 12.3 116.7 ± 14.9 112.7 ± 15.8 112.9 ± 17.2 0.9362 
Gr-3 118.6 ± 10.0 114.0 ± 14.3 107.4 ± 10.2 106.5 ± 14.6 109.5 ± 13.6 118.1 ± 13.6 124.8 ± 17.3 115.4 ± 13.0 116.5 ± 14.0 0.0035 
Gr-4 103.3 ± 20.4 98.6 ± 22.9 92.0 ± 24.4 92.1 ± 20.9 98.6 ± 19.5 99.7 ± 25.3 107.8 ± 23.3 100.1 ± 23.7 100.7 ± 24.9 0.0572 
 All 109.2 ± 11.8 106.6 ± 12.6 104.8 ± 12.9 104.4 ± 12.2 105.5 ± 12.3 110.0 ± 12.9 112.4 ± 13.2 105.8 ± 12.3 105.3 ± 12.3  0.7575 
 Gr-1 113.2 ± 7.5 110.3 ± 9.2 109.5 ± 10.4 108.1 ± 9.1 109.4 ± 10.8 113.5 ± 10.7 116.5 ± 11.6 110.0 ± 10.5 109.7 ± 10.8 0.8201 
%TLC 
(%) 
Gr-2 110.7 ± 12.6 109.6 ± 12.1 106.5 ± 13.2 106.0 ± 12.3 107.1 ± 12.8 114.1 ± 14.0 113.3 ± 13.7 106.6 ± 13.1 105.8 ± 13.0 0.7487 
 Gr-3 109.1 ± 12.9 107.1 ± 13.6 105.2 ± 12.9 105.2 ± 13.4 105.5 ± 12.4 109.8 ± 11.9 113.7 ± 12.7 105.2 ± 11.9 105.2 ± 11.6 0.9982 
 Gr-4 103.5 ± 12.3 99.2 ± 12.5 97.9 ± 12.8 98.2 ± 12.2 100.0 ± 12.0 102.5 ± 12.3 106.1 ± 13.3 101.4 ± 12.9 100.8 ± 13.0 0.4424 
Data are expressed as the means ± SD. *: A single regression analysis was used to express chronological trends. VC: volume capacity, FEV1: forced expiratory volume in one 
second, DLco: diffusing capacity for carbon monoxide, TLC: total lung capacity, FEV1%: FEV1/FVC ratio, Gr: group, NS: non-significant. Gr-1: serum indium level (sIn) < 3.7 
ng/ml, Gr-2: 3.7 ng/ml < sIn < 9.9 ng/ml, Gr-3: sIn 10.0 ng/ml < sIn < 22.4 ng/ml, Gr-4: 22.5 ng/ml < sIn.  
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DISCUSSION 
  We conducted a nine-year comprehensive longitudinal surveillance of indium lung after 
cessation or decrease in the exposure to inhaled indium compounds.  The sIn, KL-6, SP-D 
and the degree of interstitial lesions on HRCT decreased with the reduction in exposure to 
indium, however, in the workers with high sIn concentrations, emphysematous lesions 
increased over time. This surveillance is the longest study available to date and was 
performed in a single plant where a previous cross-sectional study was conducted.[3] The 
findings of the present study reinforce the conclusions of a recent 5-year follow-up study 
conducted in 11 factories.[17] 
 
  Improvements in the work environment with the obligatory use of room ventilators, mask 
fitting testers, and air shower booths have been implemented annually since the first reported 
case of indium-related lung disease (Figure 2).  Workers were transferred to non-indium 
sections according to the results of annual examinations based on the predetermined criteria 
(“Study design and subjects” in the MATERIALS and METHODS).  As a result, the average 
sIn concentration in the present surveillance decreased annually both in workers with high 
and low sIn.  These results therefore suggest that it is possible to eliminate deposited indium 
in the body, albeit very slowly, with continuous efforts to reduce the level of inhaled indium. 
 
  The serum KL-6 and SP-D levels have been reported to be useful markers of the disease 
activity in patients with indium lung[3] as well as interstitial pneumonia.[18 19]  In this 
study, the serum KL-6 and SP-D levels declined over the observation period, and the 
prevalence of workers with elevated serum KL-6 or SP-D levels declined significantly, 
despite that the prevalence of sIn > 3 ng/ml remained 66.7% in 2010 from 76.2% in 2002 (sIn 
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value < 3 ng/ml is a potential cut-off value for preventing interstitial lung disease from indium 
exposure[5]).  Although indium-induced interstitial pneumonia has been suggested to be 
partly attenuated by the reduction of indium exposure, the clearance of indium appears to 
require longer periods of time.  
 
The role of smoking in the pathogenesis of indium lung, especially emphysematous 
changes, must be addressed.  There were no differences among smokers, ex-smokers and 
non-smokers in the progression rate of the emphysematous score even in the highest sIn group, 
suggesting that the emphysematous change was not related to the smoking history, but rather 
caused by indium compounds.  This may be explained by the fact that the indium workers 
were relatively young and the smoking duration was short in this study (Table 1).  The small 
sample size may also be a limitation in clarifying the role of smoking in indium lung.  
 
  The validity of our scoring method using HRCT has been discussed previously.[3]  The 
interstitial changes on HRCT decreased during the first years of the study period and then 
stabilized for the remaining years.  Cummings et al.[14] reported that pathologic 
reevaluation showed evidence of cholesterol clefts and proteinaceous material in the alveoli, 
consistent with alveolar proteinosis in most Japanese cases, which was originally reported as 
pulmonary fibrosis.  We did not previously recognize, however, the interstitial changes (e.g., 
ground-glass opacity) on HRCT may have partly reflected alveolar proteinosis and diminished 
over the first few years.  This may be compatible with the hypothesis that partially reversible 
alveolar proteinosis is induced by the inhalation of indium compounds and pulmonary fibrosis 
occurs later in cases involving heavy indium deposition.  Conversely, the emphysematous 
changes gradually worsened in the group with the highest sIn concentrations.  The 
emphysematous progression of indium workers with high sIn levels were confirmed in the 
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most recent cohort study.[17]  Regarding the progress of emphysematous lesion, the 
check-valve mechanism resulting from bronchiolar obstruction by cholesterol granuloma 
formation and fibrous changes with heavy deposition of indium compounds may have 
occurred.[2 6]     
  
In the pulmonary function tests, the complicated trends observed (i.e., decreased 
FEV1/FVC and slightly improved VC and DLCO) in the high sIn groups may be attributed to 
the mixture of improved interstitial (e.g., proteinosis) and worsened emphysematous changes. 
The presence of airway obstruction accompanied by the emphysematous changes may have 
affected the FEV1/FVC, which is supported by the result that the decline of FEV1/FVC in 
Group-4 was significantly larger than that of Group-1.  In a recent study Cummings et 
al.[20] reported that abnormalities in the pulmonary function are common in ITO processing 
workers, especially those with a high sIn concentration.  Therefore, even though the present 
study did not reveal consistent changes in the FEV1, DLCO and TLC in indium workers, 
careful follow-up of the pulmonary function over a longer duration is required. 
 
In this study, the estimated median sIn half-life of decay was 8.09 years; this value was 
longer in the workers with high sIn concentrations.  We speculate that, in such workers, the 
pulmonary vasculature is more severely damaged and the blood flow to the lungs is limited, 
which subsequently prolongs the clearance of deposited indium.  Similarly, the mucociliary 
transport system may be more severely damaged in workers with a heavy indium burden, 
which may also inhibit indium clearance.  These remain to be explored together with the 
toxicity of indium on the alveolar macrophages.  Nonetheless, there were no differences in 
the average rate of decrease of sIn, KL-6 and SP-D during the nine-year period between the 
current and former workers, suggesting that indium clearance is mainly determined by the 
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amount of deposition rather than the post-exposure period. The laboratory data and HRCT 
changes in indium workers should be carefully followed with special attention to the 
evolution of indium-related lung disease, regardless of workplace transfer to 
non-indium-contaminated sections. 
 
 
CONCLUSIONS 
  The results of the present study clarified several aspects of the recently recognized 
occupational lung disease “indium lung,” and our findings suggest that 1) inhaled indium 
compounds in the lungs can only be eliminated very slowly following the reduction or 
cessation of exposure to indium, 2) the elimination of deposited indium is associated with 
decreases in the serum KL-6 and SP-D levels, and 3) although indium-induced interstitial 
changes are partially reversible, permanent emphysematous changes may occur under heavy 
exposure to indium compounds.  Therefore, it is necessary to reduce exposure to 
indium-containing particles and detect indium-related lung disorders as early as possible. 
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Figure legends 
 
 
Figure 1. Study flowchart.  
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Figure 2.  The annual trends in the environmental indium concentrations in all workplaces 
where indium compounds are handled from 2001 to 2012 (2001, six workplaces; 2002-2012, 
eight workplaces). The environmental indium concentrations were presented as the first 
evaluation values which were measured in all indium working places (the first evaluation 
value; the 95-percentile highest value estimated from the distribution curve of indium 
concentrations which are sampled in at least 6 sampling points in a work place, according to 
the Work Environment Measurement Law in Japan. The first evaluation values were 
calculated in each working places, and the geometric mean and maximum/minimum values 
were presented).   
The wet-surface-grinding machines of ITO plate were enclosed in boxes in 2001.  The 
usage of the dust respirator with a 99.9% trap rate was strictly mandatory thereafter.  From 
2002 to 2005, local exhaust and general ventilation systems were replaced by more powerful 
types.  The shoe-sole cleaners and air blowing/evacuating booths were installed at the 
entrance/exit of the working rooms in order to eliminate the contamination of particles 
containing indium which attached to the shoes and working clothes.  In 2007, a mask fitting 
tester was employed to confirm the proper use of the ventilators.  In 2009 and 2010, the 
non-circulating type local ventilation system was located, which exhausted the room air and 
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supply newly cleaned-up air.  In 2011, the dust respirators were replaced by 
electrically-driven positive pressure ventilators, of which the trap rate was 99.97%.  The air 
blowing/evacuation booths were upgraded to blow more powerfully in 2011 and 2012. 
 
 
 
Figure 3.  Chronological changes in a) interstitial and b) emphysematous lesion score on 
HRCT at four levels of the serum indium (sIn) concentration.  The data (a,b) are presented as 
the mean.  Gr: Group, Gr-1: sIn < 3.7 ng/ml, Gr-2: 3.7 ng/ml < sIn < 9.9 ng/ml, Gr-3: sIn 
10.0 ng/ml < sIn < 22.4 ng/ml, Gr-4: 22.5 ng/ml < sIn.  
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Supplement 1.  Average annual changes of the HRCT scores in each study subject and chronological trends by study years 
    HRCT scores by study year 
    AAC P* 2003 2004 2005 2006 2007 2009 2010 P**  
Interstitial 
score 
Gr-1 -0.2 (-0.7～0.0) ref  0.1 (-1.5～5.5) -0.7 (-3.0～1.0) -1.4 (-4.0～1.0) -1.1 (-3.0～2.0) -1.3 (-3.0～2.0) -1.5 (-5.0～1.0) -1.6 (-5.5～0.5) < 0.0001 
Gr-2  -0.2 (-0.6～-0.0) 0.150 -0.4 (-3.0～2.5) -1.2 (-5.0～3.5) -1.8 (-6.0～2.5) -1.8 (-5.5～1.5) -2.1 (-6.0～0.5) -1.9 (-5.5～1.0) -2.0 (-5.5～0.0) < 0.0001 
Gr-3 -0.3 (-1.0～-0.1) 0.219 -0.5 (-3.0～1.5) -1.5 (-5.5～0.5) -2.4 (-8.0～-0.5) -2.4 (-8.5～0.5) -2.7 (-8.5～-0.5) -2.6 (-8.5～-0.5) -2.6 (-8.5～0.0) < 0.0001 
Gr-4 -0.3 (-1.1～0.1) 0.447 -0.5 (-3.0～2.5) -1.1 (-5.0～4.0) -2.6 (-7.5～1.5) -2.6 (-7.0～2.0) -2.8 (-7.5～2.5) -2.5 (-7.5～2.5) -2.9 (-8.0～2.5) < 0.0001 
Emphysema 
score 
Gr-1 0.0 (-0.1～0.2) ref  0.0 (-2.0～0.5) -0.2 (-2.0～0.5) -0.2 (-2.0～0.5) -0.2 (-2.0～0.0) -0.2 (-2.0～0.5) -0.2 (-2.0～1.0) -0.1 (-2.0～1.0) 0.3523 
Gr-2 0.0 (-0.1～0.3) 0.829  0.0 (-0.5～1.0)  0.0 (-1.0～0.5)  0.0 (-1.0～0.5) -0.1 (-1.0～0.5) -0.1 (-1.0～0.5)  0.1 (-1.0～2.0)  0.1 (-1.0～2.5) 0.5704 
Gr-3 0.0 (-0.1～0.2) 0.444  0.1 (-0.5～2.0)  0.0 (-1.5～1.5) -0.1 (-1.0～1.0)  0.0 (-1.0～1.0)  0.0 (-1.5～2.0)  0.1 (-1.0～2.0)  0.2 (-0.5～2.0) 0.1977 
Gr-4 0.2 (-0.1～1.2) < 0.001  0.3 (-1.0～2.5)  0.3 (-1.0～2.5)  0.7 (-0.5～4.0)  1.0 (-0.5～6.0)  1.2 (-0.5～6.5)  1.4 (-0.5～6.0)   2.0 (-0.5～10.5) < 0.0001 
All data are expressed as median (range). P*: Group-1 was allocated ass a reference group and Steel's rank-sum test was applied. P**: p for test for 
chronological trend by applying a single regression model. AAC: Average annual changes. ref: reference, Gr-1: serum indium level (sIn) < 3.7 ng/ml, 
Gr-2: 3.7 ng/ml < sIn < 9.9 ng/ml, Gr-3: sIn 10.0 ng/ml < sIn < 22.4 ng/ml, Gr-4: 22.5 ng/ml < sIn.  
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Supplement 2.   
 
Average annual changes of the pulmonary function tests in each study subject 
 %VC (%) %FEV1 (%) FEV1% (%) %DLCO (%) %TLC (%) 
 
AAC P* AAC P* AAC P* AAC P* AAC P* 
Gr-1 0.6 ± 0.5 ref 0.1 ± 1.4 ref -0.3 ± 0.6 ref 0.8 ± 1.7 ref 0.1 ± 0.7 ref 
Gr-2 0.9 ± 0.5 0.300 0.0 ± 0.5 0.990 -0.6 ± 0.4 0.249 0.5 ± 1.2 0.771 -0.1 ± 0.7 0.769 
Gr-3 1.0 ± 0.4 0.137 0.4 ± 0.4 0.652 -0.5 ± 0.4 0.683 0.7 ± 1.1 0.988 0.0 ± 0.5 0.985 
Gr-4 1.0 ± 0.9 0.050 0.3 ± 0.7 0.879 -0.7 ±0.5 0.045 0.6 ± 1.7 0.884 0.3 ± 1.0 0.703 
All data are expressed as mean ± SD.  p*: Group-1 was allocated as a reference group and Dunnett's t-test was applied. VC: volume capacity, 
FEV1: forced expiratory volume in one second, DLco: diffusing capacity for carbon monoxide, TLC: total lung capacity, FEV1%: FEV1/FVC ratio,  
AAC: Average annual changes, Gr: group, ref: reference, Gr-1: sIn < 3.7 ng/ml, Gr-2: 3.7 ng/ml < sIn < 9.9 ng/ml, Gr-3: sIn 10.0 ng/ml < sIn < 22.4 
ng/ml, Gr-4: 22.5 ng/ml < sIn. 
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